Neuroleptic malignant syndrome induced by perospirone [5]

International Journal of Neuropsychopharmacology

Volumn 9, Issue 5, 2006, Pages 635-636

  Nakagawa, Makiko ^b   Matsumura, Takehiko ^a   Kato, Daiji ^a   Kishida, Ikuko ^a   Kawanishi, Chiaki ^a   Tamura, Kouichi ^a   Hirayasu, Yoshio ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION YOKOHAMA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DANTROLENE; PEROSPIRONE;

ADULT; ANAMNESIS; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; LETTER; NEUROLEPTIC MALIGNANT SYNDROME; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; INDOLES; ISOINDOLES; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; THIAZOLES;

EID: 33750220335     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006292     Document Type: Letter

References (7)

1. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (2004). Neuroleptic malignant syndrome and atypical antipsychotic drugs. Journal of Clinical Psychiatry 65, 464-470.
2. Caroll BT (2000). The Universal Field hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectrums 5, 26-33.
3. Chakraborty N, Johnston T (2004). Aripiprazole and neuroleptic malignant syndrome. International Clinical Psychopharmacology 19, 351-353.
4. Kawanishi C (2003). Genetic predisposition to neuroleptic alignant syndrome: implications for antipsychotic therapy. American Journal of Pharmacogenomics 3, 89-95.
5. Ohno Y, Ishida-Tokuda K, Ishibashi T, Sakamoto H, Tagashira R, Horisawa T, Yabuuti K, Matsumoto K, Kawabe A, Nakamura M (1997). Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone. Polish Journal of Pharmacology 49, 213-239.
6. Onrust SV, McClellan K (2001). Perospirone. CNS Drugs 15, 329-337.
7. Murty RG, Mistry SG, Sandeep G, Chacko RC (2002). Neuroleptic malignant syndrome with zyprasidone. Journal of Clinical Psychopharmacology 22, 624-626.